Skip to content

PTHS PTHS Commercial operations — Net loss

Other segment segments

Research and Development operations
$55K+103%

Similar metrics at other companies

The Bancorp logo
TBBKCommercial — Net Income Loss
$5.64M+181%
Medallion Financial logo
MFINCommercial Lending — Profit Loss
$454K-90.8%
JBG SMITH Properties logo
JBGSCommercial — Net Operating Income Loss
$34.78M+5.8%
Huron Consulting Group logo
HURNCommercial: — Operating Income (Loss)
$14.9M+31.9%
Envela logo
ELACommercial — Operating Income
$5.78M+94.2%
First Hawaiian, Inc. logo
FHBCommercial Banking Business — Net Income Loss
$31.38M+2.1%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+92.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's commercial operations — net loss.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's commercial operations — net loss?
PTHS (PTHS) reported commercial operations — net loss of -$10.29M in Q1 2026.
What does commercial operations — net loss mean?
This metric measures the negative financial result of the commercial operations segment after deducting all operating expenses, research and development costs, and taxes from segment revenue. It highlights the profitability gap that must be bridged as the segment scales its commercial activities. Investors use this to assess the operational efficiency and the burn rate associated with bringing new therapeutics to market.